Project Grant W81XWH0810759

Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $151,040 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) effective January 16, 2026, with completion targeted for July 31, 2028. This award supports a research training and development initiative focused on investigating the role of interferon gamma (IFNγ) in promoting metastasis and immune evasion in triple negative breast cancer (TNBC). The project comprises two primary...

The National Cancer Institute (NCI), under the federal Cancer Biology Research grant program (CFDA 93.396), awarded a $218,089 Project Grant to the University of California, Santa Barbara (UCSB) to develop and evaluate a novel chimeric antigen receptor macrophage (CAR-M) immunotherapy for the treatment of triple-negative breast cancer (TNBC). The project, titled "RAC-Enhanced Chimeric Antigen Receptor-Macrophage (RACE-CAR-M) Immunotherapy for Triple Negative Breast Cancer," aims to...

This federal Project Grant award, provided by the Department of Defense's Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), is funding research at the University of Texas Southwestern Medical Center (UT Southwestern) to define the role of the RCOR2 gene in hypoxia-induced immune evasion and its potential therapeutic applications for triple-negative breast cancer. The $1.64 million award, effective from June 1, 2024 through May 31, 2027, will support...

The Case Western Reserve University will receive $1,168,656 in funding from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420) to support the project "FADD: A MECHANISTIC BASIS AND THERAPEUTIC OPPORTUNITY FOR OVERCOMING CDK4/6 INHIBITOR RESISTANCE" from April 1, 2023 to March 31, 2026. Through this three-year Project Grant, Case Western Reserve University researchers will investigate mechanisms of resistance to...

This federal Project Grant award of $378,444, provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), will support research by Trustees of Indiana University, Indianapolis to investigate the role of Heat Shock Factor 1 (HSF1) in regulating immune cell infiltration into metastatic breast tumors. The goal is to determine how HSF1 activity impacts the recruitment of CD8+ T cells and other anti-tumor immune cells to metastatic breast cancer, with the...

Yale University received a $482,312 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective April 2, 2026, through March 31, 2031. The award funds research to develop a novel therapeutic approach for inactivating regulatory T (Treg) cells through targeted protein degradation as a strategy to overcome immunotherapy resistance in cancer patients. The research builds on preliminary findings demonstrating that degradation of...

This $284,201.82 Project Grant from the National Cancer Institute, a division of the Department of Health and Human Services, will fund research into malignant cell engagement in immune circuits of human colorectal cancer. The Broad Institute, Inc. will utilize single cell RNA sequencing data from over 700,000 malignant, immune, and stromal cells from colorectal cancer patients to test the hypothesis that malignant cells expressing interferon-stimulated genes acutely promote anti-tumor immunity,...

This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) provides $170,640 to the Dana-Farber Cancer Institute in Massachusetts to support research into the role of histone cleavage in breast cancer. The project aims to investigate how the histone demethylase KDM4C drives tumor growth in triple-negative breast cancer, a subtype with high treatment resistance and metastasis risk. Key objectives include determining if KDM4C prevents proteolytic...

This federal Project Grant award from the Department of Health and Human Services National Institutes of Health National Cancer Institute, under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $613,054 to St. Jude Children's Research Hospital Inc. to study the mechanisms by which transcription factors control different cell states in neuroblastoma, a high-risk pediatric tumor. The key objectives are to 1) interrogate how master transcription factors control the...

The U.S. Defense Health Agency awarded a $907,170 Project Grant to the Provincial Health Services Authority (operating as BC Cancer) in Canada. This grant, provided under the Department of Defense's Military Medical Research and Development program (CFDA 12.420), supports research on therapeutic targeting of genomic instability in triple-negative breast cancer. The 3-year project, running from September 2023 to September 2026, aims to advance the understanding and treatment of this aggressive...